FDA
-
-
-
-
-
-
-
CEL-SCI plans U.S. study and Saudi deal for head and neck drug
-
-
-
-
-
-
-
CEL-SCI closes $7.2 million public offering of common stock
-
-
-
-
-
-
-
CEL-SCI Reports Fiscal 2025 Results
-
-
-
-
-
-
-
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
CEL-SCI partners with Saudi pharma firm for cancer drug approval
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Announces Proposed Public Offering
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) to File for Regulatory Approval of Multikine in Saudi Arabia—Pursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market
-
325,451 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

